Could inhibition of C1q effectively halt the progression of GA? Joel Pearlman, MD, sat down to discuss findings from the phase 2 ARCHER study, which evaluated ANX007 (Annexon) in patients with GA. He tells us what happened when patients were dosed with ANX007 for 1 year—and what occurred when...
Published 09/05/24
Does switching long-term wet AMD patients to faricimab (Vabysmo, Genentech/Roche) result in meaningful change to disease presentation? Join New Retina Radio Journal Club host Ben Young, MD, MS, and panelists Lediana Goduni, MD, and Josh Uhr, MD, as they break down a recent real-world study...
Published 08/29/24